THE BOARD
The company’s board of directors has a proven track record of success in advancing therapies to treat both rare diseases and dermatologic diseases and conditions
BOARD MEMBERS
Mr. Ran Nusbaum
Ran Nussbaum is a managing partner and co-founder of Pontifax. The fund runs more than 50 portfolio companies around the Globe. Ran’s work revolves around constant and active involvement in companies, providing them with strategic and business development oversight. In the past Ran served on Kite pharma BOD (sold to Gilead), cCAM Therapeutics (sold to Merck), and ArQule (sold to Merck), and Prevail Therapeutics (sold to Lilly). He also chaired Ocon Medical, Nasvax, Spearhead, and Biomedix. Currently, Ran sits on many of Pontifax’s portfolio companies including Eloxx Therapeutics (ELOX), and UroGen (URGN). Ran also serves as Keros Therapeutics (KROS) chairman of the board.
Dr. Silvi Nioman
Dr. Silvia Noiman is a serial entrepreneur and leading executive with over 30 years’ experience in the Life Science Industry. She is currently the founder, and CEO of Imel Biotherapeutics. Silvia served as a Venture Partner at Pontifax and founded many of Pontifax’s portfolio companies, including cCAM Biotherapeutics (acquired by Merck), and Eloxx Pharmaceuticals where she served as CEO and board member bringing the company from inception to an IPO (Nasdaq: ELOX) and phase 2 clinical trials. Prior to joining Pontifax, she was Founder and Senior Vice President at Predix Pharmaceuticals, bringing a small early-stage drug discovery company from inception to a $500M publicly traded multi-product company (Nasdaq: EPIX). Silvia holds a Ph.D. in Molecular Biology and MBA from Tel Aviv University and Post Doc from the Weizmann Institute of Science.
Dr. Pini Orbach
Dr. Pini Orbach joined Arkin Holdings in 2010 as head of its pharma division. He sits on the board of several of Arkin’s pharmaceutical companies, including UroGen Pharma and Quiet Therapeutics, with which he shares his extensive hands-on experience in drug development and business.
Dr. Orbach’s gained his professional record in US-based companies such as Arisaph Pharmaceuticals and Epix Pharmaceuticals (NASDAQ: EPIX), as well as Israel-based companies such as cCAM BioTherapeutics, a cancer immunotherapy company sold to Merck in 2015 for $605M
He holds a Ph.D from the Department of Physiology and Functional Genomics at the University of Florida, and was a postdoctoral fellow at the Cardiovascular Research Center, Harvard Medical School, Massachusetts General Hospital.